查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2012953

生物製药物流市场：依产品类型、服务类型、运输方式、温度需求及最终用户划分－2026-2032年全球市场预测

Bio-Pharmaceutical Logistics Market by Product Type, Service Type, Mode Of Transport, Temperature Requirement, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，生物製药物流市场价值将达到 187.1 亿美元，到 2026 年将成长至 206.9 亿美元，到 2032 年将达到 407.7 亿美元，复合年增长率为 11.76%。

主要市场统计数据
基准年 2025 187.1亿美元
预计年份：2026年 206.9亿美元
预测年份 2032 407.7亿美元
复合年增长率 (%) 11.76%

对现代生物製药物流格局进行深入分析，重点关注技术融合、监管收紧以及建立具有韧性的供应链所面临的策略挑战。

生物製药物流领域正面临着由科学进步、监管加强和地缘政治动态共同驱动的日益复杂的局面。运输临床实验药物、生技药品、血液製品和疫苗的公司，在日益分散的全球网路中，对严格的温度控制、可追溯性和合规性提出了更高的要求。因此，物流领导者必须平衡两大挑战：既要最大限度地降低产品完整性风险，也要维持分销和临床供应链的速度和成本效益。

温度控制、监管整合、数位控制塔和永续发展压力如何将生物製药物流转变为以产能为主导的服务模式。

在生物物流产业，正在发生多项变革性变化，重新定义了人们对物流速度、安全性和品质的期望。首先，温控操作正从单纯的合规要求转变为策略性功能，相关人员要求提供涵盖低温、冷冻、冷藏和常温要求的端到端低温运输保障。这种转变不仅推动了对隔热包装和主动控制容器的投资，也推动了对即时遥测技术的投资，从而能够提供整个运输过程中的详细可视性。

近期关税趋势的多方面累积影响正在重塑生物製药物流领域的采购、运输选择、海关专业知识要求和区域基础设施投资。

美国在2025年前逐步实施的关税政策对生物製药物流产生了累积影响，其影响范围远不止于表面的关税税率，还涵盖了运输路线选择、供应商选择和库存管理等各个方面。不断增加的关税负担推高了陆路运输成本，促使企业重新评估其采购和运输组合，以确保关键生产组件和成品生物製药的供应。因此，许多相关人员正根据产品重要性和时间限制对供应链进行细分，试图确定哪些货运值得采用高价空运，哪些可以整合到成本较低的海运或铁路运输路线中。

详细的細項分析揭示了服务范围、运输方式、温度等级、产品类型和最终用户期望如何共同决定营运需求和策略投资。

精细化的市场细分观点揭示了不同服务类型、运输方式、温度等级、产品类型和最终用户之间的不同需求模式、营运要求和商业机会。基于服务类型，该生态系统包括低温运输包装、清关、货运代理、仓储和配送以及附加价值服务。附加价值服务本身包括配套服务、贴标服务和品质检验。这种功能分布凸显了供应商需要将技术处理能力与合规性和产品准备能力结合。依运输方式划分，货物可透过空运、铁路、陆运和海运。每条路线在速度、成本和环境波动风险方面都存在权衡，因此需要针对每条路线制定最佳包装策略和紧急时应对计画。

美洲、欧洲、中东和非洲以及亚太地区在基础设施投资、监管复杂性和临床领域成长方面的差异，如何推动区域专业化和运输能力的扩张。

区域趋势正在塑造全部区域需求模式、基础设施建设和监管协调方面的差异。在美洲，投资集中于扩大区域冷藏保管能力，并延伸连接沿海进口枢纽与内陆製造地和临床试验中心的多模态走廊。该地区也高度重视关键治疗药物的隔日达和当日达配送模式，这推动了对检验的温控专用航空货运服务和本地「最后一公里」配送专家的需求。

对于服务生物製药产业客户的物流供应商而言，一体化的全球规模、专业的低温运输技术、检验的本地基础设施和战略伙伴关係，才是赋予他们决定性竞争优势的关键。

该产业的竞争格局由全球物流整合商、专业低温运输营运商以及融入医药分销生态系统的服务供应商组成。市场领导，检验多模态临床试验物流和高优先级末端配送服务的利基供应商可以透过提供客製化处理方案、快速反应团队以及在特定治疗领域的深厚专业知识，确立其领先地位。

为物流主管提供切实可行的建议，包括：整合可视性、检验的基础设施、海关专业知识和基于风险的商业模式，以保护对温度敏感的物流流动。

产业领导者应采用以四项互补优先事项为核心的策略框架，以确保产品完整性和业务永续营运。首先，透过实施可互通的遥测技术、数位化监管链系统和集中式控制塔，实现端到端的可视性，从而实现预测性路线规划和快速异常管理。这种方法可以缩短停留时间，提高监管审计的准备程度，并增强复杂多模态物流的决策能力。其次，优先投资于检验基础设施，例如区域冷库、低温处理中心和认证包装材料库，以支援在不同温度条件下扩充性且合规的配送。

透过高度透明的混合方法研究，结合对从业者的访谈、情境分析和营运案例研究，我们获得了关于物流能力差距和解决方案的可重复见解。

本研究途径结合了对行业相关人员的初步调查以及对营运实践的系统性回顾，以得出基于证据的见解。初步研究包括对供应链负责人、低温运输工程师、品质保证经理和物流服务供应商进行结构化访谈，以收集关于处理流程、包装验证和异常管理的第一手观点。这些定性资讯与已记录的监管指南和公开的最佳实践进行交叉比对，以确保分析的严谨性和可操作性。

总之，综合讨论强调了实现稳健的药品分销需要综合可视性、检验的温度控制、海关清关能力和战略伙伴关係。

总而言之，生技药品、血液製品和疫苗的有效分销需要对物流策略进行全面重组，转向以可视性为中心、检验且本地化优化的解决方案。持续的关税和监管压力正在加速本地化和近岸外包的趋势，同时也提升了清关能力和综合服务交付的价值。能够将多模态专业知识与检验的包装、低温处理能力和综合品质检验相结合的供应商，最能满足现代治疗药物分销的严苛要求。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生物製药物流市场：依产品类型划分

  • 生物製药
  • 血液製品
  • 疫苗

第九章：生物製药物流市场：依服务类型划分

  • 低温运输包装
  • 报关
  • 转发
  • 仓储/配送
  • 附加价值服务
    • 套件组装服务
    • 标籤服务
    • 品质检验

第十章：以运输方式分類的生物製药物流市场

  • 航空
  • 铁路
  • 土地
  • 海上运输

第十一章：依温度要求分類的生物製药物流市场

  • 环境的
  • 极低温度
  • 冰冻
  • 冷藏

第十二章：生物製药物流市场：依最终用户划分

  • 诊所
  • CRO（药物研发合约研究组织）
  • 医院
  • 製药公司
  • 研究机构

第十三章：生物製药物流市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：生物製药物流市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：生物製药物流市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国生物製药物流市场

第十七章：中国生物製药物流市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agility Public Warehousing Company KSCP
  • Air Canada Cargo Inc.
  • Almac Group Limited
  • AmerisourceBergen Corporation
  • Biocair Limited
  • CH Robinson Worldwide, Inc.
  • Cardinal Health, Inc.
  • CEVA Logistics AG
  • Cryoport Inc.
  • DB Schenker
  • Deutsche Post DHL Group
  • DSV Panalpina A/S
  • FedEx Corporation
  • GEODIS SA
  • Kerry Logistics Network Limited
  • Kuehne+Nagel International AG
  • MNX Global Logistics LLC
  • Movianto Group
  • Nippon Express Co., Ltd.
  • PCI Pharma Services Holdings LLC
  • QuickSTAT Global Life Science Logistics Inc.
  • SF Express Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • United Parcel Service, Inc.
  • World Courier Inc.
Product Code: MRR-437D459587C9

The Bio-Pharmaceutical Logistics Market was valued at USD 18.71 billion in 2025 and is projected to grow to USD 20.69 billion in 2026, with a CAGR of 11.76%, reaching USD 40.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.71 billion
Estimated Year [2026] USD 20.69 billion
Forecast Year [2032] USD 40.77 billion
CAGR (%) 11.76%

An incisive introduction to the contemporary bio-pharmaceutical logistics environment highlighting technological convergence, regulatory intensity, and strategic imperatives for resilient supply chains

The bio-pharmaceutical logistics landscape is confronting an era of intensifying complexity driven by scientific advances, regulatory scrutiny, and shifting geopolitical dynamics. Companies that move investigational products, biologics, blood products, and vaccines face heightened demands for exacting temperature control, traceability, and compliance across increasingly bifurcated global networks. Consequently, logistics leaders must reconcile the dual imperatives of minimizing risk to product integrity while maintaining speed and cost-efficiency in distribution and clinical supply chains.

Moreover, the industry is experiencing a convergence of technology adoption, such as digital temperature monitoring and blockchain-enabled provenance tracking, with operational redesigns including nearer-shore manufacturing and multi-modal transport strategies. This convergence is reshaping the playbook for providers and shippers alike, as service models evolve to integrate value-added functions such as kitting, labeling, and quality inspection directly into distribution workflows. As a result, stakeholders across the value chain are rethinking partnerships, contracting frameworks, and capital allocation to support resilient, compliant pathways from manufacturing to patient.

In this context, strategic foresight and operational dexterity become the differentiators. Leaders must prioritize data-driven visibility, regulatory harmonization, and contingency capacity in order to mitigate disruptions. The following sections unpack the transformative shifts, tariff-driven headwinds, segmentation nuances, regional dynamics, and actionable recommendations that together define the contemporary bio-pharmaceutical logistics imperative.

How temperature assurance, regulatory convergence, digital control towers, and sustainability pressures are jointly transforming bio-pharmaceutical logistics into capability-driven service models

The industry is undergoing several transformative shifts that are recalibrating expectations for speed, security, and quality in bio-pharmaceutical logistics. First, temperature-sensitive handling has moved from a compliance checkbox to a strategic capability, with stakeholders demanding end-to-end cold chain assurance that spans cryogenic, frozen, refrigerated, and ambient requirements. This shift is driving investment not only in insulated packaging and active-controlled containers but also in real-time telemetry that provides granular visibility across every transport leg.

Second, regulatory harmonization and inspection rigor are increasing simultaneously, prompting operators to formalize standardized documentation, calibration protocols, and digital audit trails. This trend is interlinked with the rise of decentralized clinical trials and the need to move smaller, higher-value shipments to geographically dispersed sites with consistent quality controls. Consequently, logistics providers are layering value-added services-ranging from kitting and labeling to in-line quality inspection-closer to point-of-care or regional distribution centers.

Third, technology adoption is accelerating systemic improvements in routing, customs clearance, and exception management. Predictive analytics and integrated control towers are enabling dynamic decisioning that reduces dwell time at borders and optimizes mode selection between air, road, rail, and sea based on cost, speed, and product fragility. Finally, sustainability considerations and cost pressures are incentivizing modal shifts and packaging innovation, as stakeholders seek lower-carbon pathways without compromising the integrity of biologics and vaccines. Taken together, these shifts represent a reorientation from transactional logistics to a consultative, capability-driven model that prioritizes product safety and commercial continuity.

The multifaceted cumulative effects of recent tariff dynamics reshaping sourcing, modal choices, customs expertise requirements, and regional infrastructure investment in bio-pharmaceutical logistics

The imposition and evolution of tariffs in the United States through 2025 have had a cumulative effect on bio-pharmaceutical logistics that extends beyond headline duty rates to influence routing decisions, supplier selection, and inventory posture. Rising tariff burdens increase landed costs and incentivize companies to reevaluate sourcing footprints and modal mixes to preserve access to critical manufacturing components and finished biologics. As a result, many stakeholders are exploring supply chain segmentation by criticality of product and time-sensitivity to determine which flows justify premium air transport and which can be consolidated and routed via lower-cost sea or rail corridors.

In practice, tariff-driven adjustments translate into longer transit leg optimization exercises and increased reliance on customs clearance expertise. Logistics providers with embedded customs brokerage capabilities and hardened documentation workflows are capturing higher-value roles because they reduce clearance friction and minimize the risk of temperature excursions due to border delays. Furthermore, tariffs have catalyzed nearshoring and regionalization strategies that compress cross-border transit times; this shift increases demand for regional cold storage and distribution nodes and stimulates investment in specialized infrastructure such as validated storage rooms and cryogenic handling facilities.

Another consequential impact is the reconfiguration of contract terms and insurance structures, where shippers seek clearer allocation of tariff risk and expedited claims procedures for temperature-related loss. In tandem, procurement teams are pushing for greater transparency in landed cost models that account for duties, surcharges, and compliance obligations. Altogether, tariffs have accentuated the need for integrated trade compliance, adaptive logistics planning, and strategic partnerships that can absorb regulatory volatility while safeguarding the quality and continuity of biopharmaceutical flows.

Detailed segmentation analysis revealing how service scope, transport modes, temperature classes, product types, and end-user expectations jointly define operational requirements and strategic investments

A granular segmentation lens reveals distinct demand patterns, operational requirements, and commercial opportunities across service types, transport modes, temperature classes, product categories, and end users. Based on service type, the ecosystem encompasses Cold Chain Packaging, Customs Clearance, Freight Forwarding, Storage And Distribution, and Value Added Services, where Value Added Services itself includes Kitting Services, Labeling Services, and Quality Inspection; this distribution of functions underscores the imperative for providers to bundle technical handling with compliance and product preparation capabilities. When examined by mode of transport, shipments traverse Air, Rail, Road, and Sea corridors, each offering tradeoffs between speed, cost, and exposure to environmental variation, and requiring bespoke packaging strategies and contingency planning.

Temperature requirement segmentation further differentiates operational practices: Ambient flows demand minimal thermal control but rigorous contamination safeguards, Refrigerated shipments require validated temperature windows and continuous monitoring, Frozen transport imposes stricter containerization and holding-time constraints, and Cryogenic logistics introduces specialized equipment and handling protocols for ultra-low temperatures. Product type segmentation-covering Biologics, Blood Products, and Vaccines-adds another layer of differentiation, since biologics and vaccines frequently necessitate batch-level traceability, expedited customs processing, and prioritized transport lanes, while blood products often require rapid, localized distribution networks and stringent donor-origin tracking.

Finally, end user segmentation including Clinics, Contract Research Organizations, Hospitals, Pharmaceutical Companies, and Research Institutes determines service expectations and SLA structures. Clinics and hospitals demand reliability and predictable last-mile performance, contract research organizations and research institutes prioritize secure handling for clinical trial materials, and pharmaceutical companies typically seek integrated solutions that combine global forwarding, validated storage, and quality oversight. Synthesizing these segmentation dimensions clarifies where investments in technology, validated assets, and specialized personnel will create the greatest operational leverage and commercial differentiation.

How differing infrastructure investments, regulatory complexity, and clinical growth across the Americas, Europe Middle East & Africa, and Asia-Pacific are driving regional specialization and capacity build-out

Regional dynamics are shaping differential demand patterns, infrastructure development, and regulatory harmonization efforts across major geographies. In the Americas, investments are concentrated on scaling regional cold storage capacity and expanding multi-modal corridors that link coastal import hubs with inland manufacturing and clinical trial centers. This region is also characterized by a pronounced focus on single-day and same-day delivery models for critical therapies, which drives demand for dedicated air freight services and local last-mile specialists capable of validated handoffs and temperature assurance.

Europe, Middle East & Africa presents a complex overlay of regulatory regimes and distribution geographies. This region is investing in interoperable digital documentation and customs data exchange to reduce cross-border friction, while advanced European markets emphasize sustainability alongside high regulatory standards, spurring demand for packaging innovation and consolidated distribution platforms. Emerging markets within the region add another layer of operational complexity, where constrained cold infrastructure and variable road quality require hybrid solutions that combine centralized cold hubs with robust last-mile packaging and monitoring.

Asia-Pacific is witnessing rapid expansion of biologics manufacturing capabilities and an uptick in clinical activity, which together are driving investments in validated storage, air freight capacity, and cold chain packaging innovation. Cross-border intra-regional trade is increasingly important, prompting logistics providers to build regional networks that minimize transit times and leverage rail and sea corridors as cost-effective alternatives to long-haul air. Across all regions, regulatory synchronization, digital visibility, and investment in validated assets are the primary levers for reducing product risk and enabling scalable distribution of temperature-sensitive therapies.

Why integrated global scale, specialized cold chain expertise, validated local infrastructure, and strategic partnerships are the decisive competitive levers for logistics providers serving biopharmaceutical customers

Competitive dynamics in the sector are shaped by a mixture of global logistics integrators, specialized cold chain operators, and service providers embedded within pharmaceutical distribution ecosystems. Market leaders that combine global forwarding scale with temperature-controlled asset ownership are increasingly favored for complex global programs because they can offer validated storage, multi-modal routing, and integrated customs clearance under a single contractual umbrella. Conversely, niche providers that concentrate on clinical trial logistics or high-acuity last-mile services can command premium positioning by delivering tailored handling protocols, rapid response teams, and deep therapeutic-area expertise.

Partnership models are also evolving, as pharmaceutical manufacturers seek closer collaboration with logistics partners through long-term contracts, shared-risk frameworks, and jointly developed quality systems. Technology partnerships that enable telemetry, chain-of-custody documentation, and centralized control towers are particularly valued for their ability to reduce dwell time and provide auditable data for regulatory inspections. Moreover, companies that invest in local validated infrastructure-such as GMP-compliant storage rooms and cryogenic handling centers-are better positioned to capture the growing volume of regionally distributed biologics and clinical supplies.

Finally, consolidation and selective alliances are reshaping service offerings, with some global integrators forming strategic relationships with specialized cold chain specialists to extend capability breadth without diluting quality controls. These alliances create differentiated propositions by combining operational scale, regulatory know-how, and domain-specific handling expertise, thereby addressing the full spectrum of requirements from investigational product distribution to commercial biologic rollouts.

Actionable recommendations for logistics executives to embed visibility, validated infrastructure, customs expertise, and risk-aligned commercial models to protect temperature-sensitive flows

Industry leaders should adopt a strategic framework oriented around four complementary priorities to safeguard product integrity and commercial continuity. First, embed end-to-end visibility by deploying interoperable telemetry, digital chain-of-custody systems, and centralized control towers that enable predictive routing and rapid exception management. This approach reduces dwell time, enhances regulatory audit readiness, and improves decision-making across complex multi-modal flows. Second, prioritize modular investments in validated infrastructure such as regional cold storage, cryogenic handling centers, and certified packaging pools to support scalable, compliant distribution across diverse temperature profiles.

Third, strengthen trade compliance and customs brokerage capabilities through dedicated expertise and standardized documentation workflows. Robust customs performance mitigates the tariff and clearance-driven delays that can compromise temperature-sensitive shipments and disrupt clinical timelines. Fourth, align commercial models with strategic risk sharing by negotiating transparent terms that account for tariff exposure, expedited handling requirements, and claim settlement processes. These contractual structures incentivize continuous quality improvement and create clarity on liability for temperature excursions.

Collectively, these priorities should be operationalized through cross-functional governance that integrates procurement, quality assurance, cold chain engineering, and commercial teams. By instituting performance metrics tied to product integrity outcomes, response times, and documentation accuracy, organizations will be better positioned to convert logistical resilience into measurable business advantage.

Transparent mixed-method research approach combining practitioner interviews, scenario analysis, and operational case studies to derive reproducible insights into logistics capability gaps and solutions

The research approach combined primary engagement with industry stakeholders and a systematic review of operational practices to produce evidence-based insights. Primary engagement included structured interviews with supply chain leaders, cold chain engineers, quality assurance managers, and logistics service providers to capture first-hand perspectives on handling protocols, packaging validation, and exception management. These qualitative inputs were triangulated with documented regulatory guidance and publicly available operational best practices to ensure analytical rigor and practical relevance.

Analytical methods employed scenario analysis to explore the operational implications of tariff shifts and modal reconfigurations, while comparative case studies highlighted successful implementations of regional cold infrastructure and control tower architectures. Data synthesis focused on operational levers-such as packaging performance, telemetry penetration, customs clearance cycles, and validated storage capacity-rather than on speculative market sizing, enabling a pragmatic assessment of capability gaps and investment priorities. Throughout, the methodology emphasized reproducibility and transparency, with clear documentation of interview protocols, validation checks, and assumptions underpinning scenario narratives.

This mixed-methods design ensures that conclusions rest on both practitioner experience and observable operational trends, providing a robust foundation for strategic decision-making in bio-pharmaceutical logistics.

Concluding synthesis emphasizing the necessity of integrated visibility, validated temperature control, customs competence, and strategic partnerships to enable resilient therapeutic distribution

In conclusion, the effective distribution of biologics, blood products, and vaccines demands a holistic realignment of logistics strategy toward visibility-driven, validated, and regionally tuned solutions. Persistent tariff and regulatory pressures are accelerating regionalization and nearshoring trends while simultaneously elevating the value of customs competence and integrated service offerings. Providers that can combine multi-modal routing expertise with validated packaging, cryogenic handling capabilities, and embedded quality inspection will be best positioned to meet the stringent demands of modern therapeutic distribution.

Decision-makers must therefore prioritize investments that reduce exposure to border delays, enhance temperature assurance across ambient to cryogenic classes, and institutionalize digital traceability to support regulatory inspections and rapid recalls. By adopting modular infrastructure investments, forging technology-enabled partnerships, and aligning commercial terms to reflect shared risk, stakeholders can transform logistical complexity into a strategic asset that supports faster patient access, improved clinical trial integrity, and more resilient commercial supply chains. The path forward requires coordinated action across procurement, operations, quality, and commercial teams to translate these insights into measurable operational improvements.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bio-Pharmaceutical Logistics Market, by Product Type

  • 8.1. Biologics
  • 8.2. Blood Products
  • 8.3. Vaccines

9. Bio-Pharmaceutical Logistics Market, by Service Type

  • 9.1. Cold Chain Packaging
  • 9.2. Customs Clearance
  • 9.3. Freight Forwarding
  • 9.4. Storage And Distribution
  • 9.5. Value Added Services
    • 9.5.1. Kitting Services
    • 9.5.2. Labeling Services
    • 9.5.3. Quality Inspection

10. Bio-Pharmaceutical Logistics Market, by Mode Of Transport

  • 10.1. Air
  • 10.2. Rail
  • 10.3. Road
  • 10.4. Sea

11. Bio-Pharmaceutical Logistics Market, by Temperature Requirement

  • 11.1. Ambient
  • 11.2. Cryogenic
  • 11.3. Frozen
  • 11.4. Refrigerated

12. Bio-Pharmaceutical Logistics Market, by End User

  • 12.1. Clinics
  • 12.2. Contract Research Organizations
  • 12.3. Hospitals
  • 12.4. Pharmaceutical Companies
  • 12.5. Research Institutes

13. Bio-Pharmaceutical Logistics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bio-Pharmaceutical Logistics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bio-Pharmaceutical Logistics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bio-Pharmaceutical Logistics Market

17. China Bio-Pharmaceutical Logistics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agility Public Warehousing Company K.S.C.P.
  • 18.6. Air Canada Cargo Inc.
  • 18.7. Almac Group Limited
  • 18.8. AmerisourceBergen Corporation
  • 18.9. Biocair Limited
  • 18.10. C.H. Robinson Worldwide, Inc.
  • 18.11. Cardinal Health, Inc.
  • 18.12. CEVA Logistics AG
  • 18.13. Cryoport Inc.
  • 18.14. DB Schenker
  • 18.15. Deutsche Post DHL Group
  • 18.16. DSV Panalpina A/S
  • 18.17. FedEx Corporation
  • 18.18. GEODIS S.A.
  • 18.19. Kerry Logistics Network Limited
  • 18.20. Kuehne + Nagel International AG
  • 18.21. MNX Global Logistics LLC
  • 18.22. Movianto Group
  • 18.23. Nippon Express Co., Ltd.
  • 18.24. PCI Pharma Services Holdings LLC
  • 18.25. QuickSTAT Global Life Science Logistics Inc.
  • 18.26. SF Express Co., Ltd.
  • 18.27. Thermo Fisher Scientific Inc.
  • 18.28. United Parcel Service, Inc.
  • 18.29. World Courier Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY BLOOD PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY BLOOD PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY BLOOD PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COLD CHAIN PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COLD CHAIN PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COLD CHAIN PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CUSTOMS CLEARANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CUSTOMS CLEARANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CUSTOMS CLEARANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY FREIGHT FORWARDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY FREIGHT FORWARDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY FREIGHT FORWARDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY STORAGE AND DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY STORAGE AND DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY STORAGE AND DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY KITTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY KITTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY KITTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY QUALITY INSPECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY QUALITY INSPECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY QUALITY INSPECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY AIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY AIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY AIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY RAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY RAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY RAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY ROAD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY ROAD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY ROAD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY AMBIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY AMBIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY AMBIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CRYOGENIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CRYOGENIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CRYOGENIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY FROZEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY FROZEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY FROZEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY REFRIGERATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY REFRIGERATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY REFRIGERATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. GCC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GCC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 149. GCC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 150. GCC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 151. GCC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. G7 BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. G7 BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 170. G7 BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 171. G7 BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 172. G7 BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. NATO BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. NATO BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 177. NATO BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 178. NATO BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 179. NATO BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)